Analysis

Coherus Oncology, Inc. (CHRS) Stock Analysis

Coherus Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to CHRS.

websiteCHRS/analysis/CHRS

Coherus Oncology, Inc.

Coherus Oncology, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to CHRS.

Stock profile

Ticker

CHRS

Asset type

Stock

Market cap

$228.3M

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

USD

Ticker listings

Coherus Oncology, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • CHRS primary listing
  • 8C5
  • A12ETZ

Latest Coherus Oncology, Inc. news

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI® (toripalimab-tpzi)

Coherus and Zumutor Biologics Announce Clinical Collaboration to Evaluate ZM008 in Combination with LOQTORZI®

Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update

– LOQTORZI® net revenue of $11.8 million in Q1 2026 – – Patient accrual complete for 1L HCC Phase 2 randomized clinical trial for anti-IL27 casdozokitug,

Coherus Oncology to Report First Quarter 2026 Financial Results on May 11, 2026

REDWOOD CITY, Calif., May 04, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its first quarter 2026 financial results will be released afte...

Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update

– LOQTORZI® net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 – – Reduced secured and convertible debt by 90% from $480

Coherus Oncology to Report Full Year and Fourth Quarter 2025 Financial Results on March 9, 2026

REDWOOD CITY, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (Nasdaq: CHRS), today announced that its full year and fourth quarter 2025 financial results will...

Research sections

Valuation

Review valuation context for Coherus Oncology, Inc..

Future growth

Review future growth context for Coherus Oncology, Inc..

Past performance

Review past performance context for Coherus Oncology, Inc..

Financial health

Review financial health context for Coherus Oncology, Inc..

Dividend

Review dividend context for Coherus Oncology, Inc..

Management

Review management context for Coherus Oncology, Inc..

Ownership

Review ownership context for Coherus Oncology, Inc..

Other information

Review other information context for Coherus Oncology, Inc..

Community

Review community context for Coherus Oncology, Inc..